The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Digital pathology–based AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer.
 
Feyisope Eweje
Stock and Other Ownership Interests - Disati Medical; Perception Medicine Foundation
Patents, Royalties, Other Intellectual Property - Disati Medical
 
Zhe Li
No Relationships to Disclose
 
Yuchen Li
No Relationships to Disclose
 
Colin Bergstrom
No Relationships to Disclose
 
Ted Kim
No Relationships to Disclose
 
Francesca Olguin
No Relationships to Disclose
 
Sierra Willens
No Relationships to Disclose
 
Matthew Gopaulchan
No Relationships to Disclose
 
Jeffrey Nirschl
No Relationships to Disclose
 
Joel Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; D2G Oncology; Daiichi Sankyo/Astra Zeneca; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Janssen Oncology; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Nuvation Bio; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Maximilian Diehn
Leadership - Foresight Diagnostics
Stock and Other Ownership Interests - CiberMed; Foresight Diagnostics; Perception Medicine
Consulting or Advisory Role - AstraZeneca; CiberMed; Foresight Diagnostics; Gritstone Bio; Perception Medicine; Regeneron
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection assigned to Stanford University (Inst); Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst); Royalties from Foresight Diagnostics for patent licensing fees; Royalties from Roche for patent licensing fees
Travel, Accommodations, Expenses - Foresight Diagnostics; Regeneron
 
Ruijiang Li
Stock and Other Ownership Interests - Perception Medicine
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - Pending patents related to computational pathology.